QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

35,144 signal articles · 107 in last 24h · 178,660 total before filter · latest 1h ago

107last 24h

3126last 7d

511● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1820 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: ABBVSentiment:bullish neutral bearish show all (incl. clickbait)

Trefis1d agoneutral

What Could Stall AbbVie Stock's Run?

ABBV BMY JNJ LLY MRK PFE SPGI ^GSPC

MarketBeat2d agoneutral

REGENXBIO Q3 Earnings Call Highlights

MT Newswires2d agoneutral

Argus Adjusts Price Target on AbbVie to $320 From $270

Trefis2d agobullish

The One Thing To Settle Before Buying AbbVie Stock

ABBV BMY JNJ LLY MRK PFE ^GSPC

The Wall Street Journal2d agobearish

Healthcare Stocks Fall as Market Rout Spreads

ABBV JNJ LLY MRK ^GSPC

Barchart3d agoneutral

Are Wall Street Analysts Bullish on AbbVie Stock?

Simply Wall St.4d agobullish

AbbVie (ABBV) Stock Climbs As Q3 Earnings Fuel Growth Case

24/7 Wall St.5d agoneutral

AbbVie Hit a New High After Earnings. There’s More Upside Left.

MT Newswires5d agoneutral

BNP Paribas Adjusts Price Target on AbbVie to $269 From $247

MT Newswires6d agoneutral

Canaccord Genuity Adjusts Price Target on AbbVie to $338 From $290

MT Newswires6d agoneutral

Leerink Partners Adjusts Price Target on AbbVie to $325 From $279

Zacks6d agoneutral

ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

MT Newswires6d agoneutral

Goldman Sachs Adjusts Price Target on AbbVie to $313 From $294

MT Newswires6d agobullish

RBC Raises Price Target on AbbVie to $330 From $280, Keeps Outperform Rating

MT Newswires6d agoneutral

Cantor Fitzgerald Adjusts Price Target on AbbVie to $325 From $290

MT Newswires6d agoneutral

Guggenheim Adjusts Price Target on AbbVie to $322 From $288

Motley Fool8d agoneutral

AbbVie: 3 Key Takeaways for Long-Term Investors

Motley Fool8d agobullish

Is AbbVie a Buy After Its Latest Earnings Report?

Simply Wall St.8d agobullish

Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?

GuruFocus.com8d agoneutral

AbbVie Inc (ABBV) Q3 2026 Earnings Call Highlights: Raised Guidance, Immunology Momentum, and a ...

The Wall Street Journal9d agoneutral

Health Care Roundup: Market Talk

Motley Fool9d agoneutral

AbbVie (ABBV) Q3 2026 Earnings Call Transcript

24/7 Wall St.39d agoneutral

BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength

GuruFocus.com40d agobearish

AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval

Simply Wall St.40d agoneutral

Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's?

Insider Monkey41d agoneutral

Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?

TIKR41d agoneutral

AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start

GuruFocus.com41d agoneutral

AbbVie Just Won an FDA First in Parkinson's Disease

InvestorsHub41d agoneutral

AbbVie Receives FDA Approval for Parkinson’s Disease Drug Juvmo

Quartz44d agoneutral

ADARx Pharmaceuticals raises $446 million in upsized IPO